Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy
- First Posted Date
- 2014-12-16
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 38
- Registration Number
- NCT02317627
- Locations
- 🇺🇸
Clinical Studies Group, LLC, Henderson, Nevada, United States
🇺🇸Arrowhead Health Centers, Glendale, Arizona, United States
🇺🇸Metroplex Clinical Research Center (MCRC), Dallas, Texas, United States
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT02154529
- Locations
- 🇺🇸
Laura and Isaac Perlmutter Cancer Center @ NYU Langone, New York, New York, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸San Juan Oncology, Farmington, New Mexico, United States
A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT02106195
- Locations
- 🇺🇸
UC Irvine Health, Dept of Dermatology, Irvine, California, United States
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT01487174
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸San Juan Oncology Associates, Farmington, New Mexico, United States
Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Kadmon Corporation, LLC
- Registration Number
- NCT00951223
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00522145
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸Cancer Care Center, Inc. P.C., New Albany, Indiana, United States
🇺🇸Ronald Yanagihara, Gilroy, California, United States
Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT00456248
- Locations
- 🇺🇸
Atlantic Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸Caroline Digestive Health Associates, Harrisburg, North Carolina, United States
🇺🇸Liver Institute at Methodist Dallas, Dallas, Texas, United States
Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00364780
- Locations
- 🇺🇸
Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
- Conditions
- First Posted Date
- 2006-06-14
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00336765
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors
- Conditions
- First Posted Date
- 2004-07-07
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00086528
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States